Where are oral drugs absorbed?

Mostly in the small intestine. The stomach absorbs very little and acts as a metering valve controlling delivery.

Does delayed emptying reduce total drug exposure?

Often less than it reduces the peak. The drug still arrives, just more gradually — so peak concentration falls more than area under the curve.

Which drugs are most affected?

Those that must exceed a concentration threshold to work, rather than those whose effect tracks total daily exposure.

GLP-1 & Incretin Science

Slowing the Stomach Changes When a Tablet Arrives

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-232 cited sources

Most orally administered drugs are absorbed in the small intestine, not the stomach, so the rate at which the stomach empties governs when absorption begins. Delaying it delays and flattens the peak concentration, which matters most for drugs whose effect depends on reaching a threshold.

Key facts

Absorption site: Small intestine, for most oral drugs
Stomach's role: Controls delivery rate
Effect of delay: Later, lower peak concentration
Total exposure: Often less affected than peak
Most affected: Threshold-dependent drugs
Class behaviour: Not uniform — varies by compound

Why the stomach is a gate rather than an absorber

The gastric mucosa absorbs very little. The small intestine does the work, with a vastly larger surface area and the transporters most drugs rely on. So the stomach functions as a metering valve — it holds contents and releases them onward, and the rate of that release sets when the intestine can begin absorbing.

What slowing the valve does to a concentration curve

Two things, and they are separable. The peak concentration falls, because the same quantity arrives spread over a longer period. And the time to that peak lengthens. Total exposure — the area under the curve — is often less affected, because the drug eventually arrives; it simply arrives more gradually.

Research material referenced

Retatrutide 10mg — third-party HPLC tested

View — £59.99

Why the distinction between peak and total matters

It determines which drugs are affected in a way that matters. A drug whose effect tracks total exposure over a day tolerates a flattened peak. A drug that must exceed a concentration threshold to work may fail to reach it. The same pharmacokinetic change is inconsequential for one and consequential for the other.

Why incretin agonists slow gastric emptying at all

It is part of the mechanism rather than a side effect. Slowing gastric emptying prolongs the sensation of fullness and blunts the post-meal glucose rise, both of which contribute to the intended effect. Shaefer and colleagues set this out in their user's guide to the class in Postgraduate Medicine in 2015. Any consequence for co-administered oral drugs follows from the mechanism working.

Why the effect is not uniform across the class

Different compounds delay gastric emptying to different degrees, and the delay also attenuates over time with continued exposure — which is why gastrointestinal effects typically diminish after the first weeks. A compound with a stronger effect, or one escalated rapidly through doses, presents a different interaction picture from one with a milder effect at a steady dose.

What this is and is not

A description of pharmacokinetic principles and published findings about licensed medicines. It is not guidance about taking anything, and no research material supplied here is a GLP-1 receptor agonist or has any bearing on medicines a person may be prescribed.

Extended research context

The GLP-1 & Incretin Science deep dive

Deep dive: the two routes to a bigger effect

Every compound trying to beat GLP-1 alone has taken one of two routes. The first adds more receptors from the same hormone family — GIP in tirzepatide, GIP and glucagon in retatrutide. The second adds a non-incretin satiety hormone, which in practice means amylin: CagriSema combines cagrilintide with semaglutide, and amycretin engages both receptors from one molecule. Both routes work, because they recruit signalling pathways that do not fully overlap. Neither has escaped the constraint that binds all of them, which is that gastrointestinal tolerability worsens as effect size grows.

Deep dive: why a percentage is not a result

The most-quoted numbers in this field are the least comparable. REDEFINE 1 reported 22.7% and 20.4% for the same compound in the same trial — the first among participants who adhered to treatment, the second across everyone randomised. TRIUMPH-1 reported 28.3% in an uncomplicated obesity population while TRIUMPH-3 reported up to 22.6% in adults with established cardiovascular disease, using the same compound. Before any two figures can be compared they have to match on estimand, population, duration, comparator and whether the number is placebo-adjusted. Most published comparisons match on none of them.

Deep dive: what happens after the trial stops

Every headline figure describes weight while treatment continues. The STEP-1 extension found that a year after semaglutide was stopped, participants had given back roughly two-thirds of what they lost, moving from 17.3% mean reduction to a net 5.6% — though average weight remained below baseline and nearly half stayed at least 5% down. Meta-analysis puts regain at around 0.8 kg per month. This is why maintenance studies such as TRIUMPH-6 matter more to the field's future than another two points of peak reduction.

Research applications

▸Comparing incretin and amylin compounds on a like-for-like basis
▸Interpreting estimands, thresholds and placebo-adjusted figures in trial reports
▸Tracking the obesity pipeline across sponsors and jurisdictions
▸Understanding receptor pharmacology behind GLP-1, GIP, glucagon and amylin
▸Distinguishing licensed medicines from investigational compounds

Handling checklist

✓Identify which estimand a quoted percentage comes from before citing it
✓Check the trial population and baseline BMI against the comparison you are making
✓Confirm the duration and whether the reduction curve had plateaued
✓Read discontinuation rates alongside efficacy figures
✓Verify every NCT identifier against ClinicalTrials.gov rather than secondary reporting

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Comparing headline percentages across different trials

Fix: Population, duration, estimand and comparator all differ; the numbers are not interchangeable.

✗ Quoting the larger of two figures from the same trial

Fix: Name the estimand. Efficacy and treatment-policy answer different questions.

✗ Treating peak reduction as a durable outcome

Fix: Substantial regain follows cessation across the class; peak figures describe a maintained state.

✗ Assuming an oral route means a weaker mechanism

Fix: Route and receptor count are independent. Orforglipron is weaker because it hits one receptor, not because it is a tablet.

✗ Reading investigational compounds as available treatments

Fix: Most of this pipeline holds no authorisation anywhere; mazdutide is approved only in China.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Where are oral drugs absorbed?: Mostly in the small intestine. The stomach absorbs very little and acts as a metering valve controlling delivery.
Does delayed emptying reduce total drug exposure?: Often less than it reduces the peak. The drug still arrives, just more gradually — so peak concentration falls more than area under the curve.
Which drugs are most affected?: Those that must exceed a concentration threshold to work, rather than those whose effect tracks total daily exposure.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More GLP-1 & Incretin Science articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum